Phospholipid-based prodrugs for drug targeting in inflammatory bowel disease: Computational optimization and in-vitro correlation

Current Topics in Medicinal Chemistry

Volumn 16, Issue 23, 2016, Pages 2543-2548

  Dahan, Arik ^a   Ben Shabat, Shimon ^a   Cohen, Noa ^a   Keinan, Shahar ^b   Kurnikov, Igor ^b   Aponick, Aaron ^c   Zimmermann, Ellen M ^d  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b Cloud Pharmaceuticals Inc   (United States)

^c University of Florida ^*  (United States)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Drug targeting; Inflammatory bowel disease (IBD); Molecular dynamics; Phospholipase A2 (PLA2); Prodrugactivating enzyme; Thermodynamic integration; Umbrella sampling WHAM methods

Indexed keywords

INDOMETACIN; PHOSPHOLIPASE A2; PHOSPHOLIPID DERIVATIVE; PRODRUG; PHOSPHOLIPID;

ARTICLE; COMPUTER MODEL; DRUG TARGETING; HISTOGRAM; HYDROLYSIS; INFLAMMATORY BOWEL DISEASE; MATHEMATICAL MODEL; MOLECULAR MODEL; THERMODYNAMICS; CHEMISTRY; DRUG DELIVERY SYSTEM; HUMAN; IN VITRO STUDY; INFLAMMATORY BOWEL DISEASES; METABOLISM;

DRUG DELIVERY SYSTEMS; HUMANS; IN VITRO TECHNIQUES; INFLAMMATORY BOWEL DISEASES; MODELS, MOLECULAR; PHOSPHOLIPASES A2; PHOSPHOLIPIDS; PRODRUGS;

EID: 84979233617     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026616666160414122913     Document Type: Article

References (24)

1. A. Dahan.; M. Khamis.; R. Agbaria.; R. Karaman. Targeted prodrugs in oral drug delivery: the modern molecular biopharmaceutical approach. Expert Opin. Drug Deliv., 2012, 9, 1001-1013.
2. A. Dahan.; E. Zimmermann.; S. Ben-Shabat. Modern prodrug design for targeted oral drug delivery. Molecules, 2014, 19, 16489.
3. H.-K. Han.; G.L. Amidon. Targeted prodrug design to optimize drug delivery, AAPS. PharmSci., 2000, 2, 48-58.
4. A. Dahan.; O. Wolk.; Y.H. Kim.; C. Ramachandran.; G.M. Crippen.; T. Takagi.; M. Bermejo.; G.L. Amidon. Purely in silico BCS classification: Science based quality standards for the world’s drugs. Mol. Pharm., 2013, 10, 4378-4390.
5. O. Wolk.; R. Agbaria.; A. Dahan. Provisional in-silico biopharmaceutics classification (BCS) to guide oral drug product development. Drug Des. Devel. Ther., 2014, 8, 1563-1575.
6. A. Dahan.; G.L. Amidon.; E.M. Zimmermann. Drug targeting strategies for the treatment of inflammatory bowel disease: a mechanistic update, Expert Rev. Clin. Immunol., 2010, 6, 543-550.
7. O. Wolk.; S. Epstein.; V. Ioffe-Dahan.; S. Ben-Shabat.; A. Dahan. New targeting strategies in drug therapy of inflammatory bowel disease: mechanistic approaches and opportunities, Expert Opin. Drug Deliv., 2013, 10, 1275-1286.
8. M. Kurz.; G.K.E. Scriba. Drug-phospholipid conjugates as potential prodrugs: synthesis, characterization, and degradation by pancreatic phospholipase A2. Chem. Phy. Lipids, 2000, 107,143-157.
9. J.P. Laye, J.H. Gill. Phospholipase A2 expression in tumours: a target for therapeutic intervention? Drug Discov. Today, 2003, 8, 710-716.
10. A. Dahan.; R. Duvdevani.; E. Dvir.; A. Elmann.; A. Hoffman. A novel mechanism for oral controlled release of drugs by continuous degradation of a phospholipid prodrug along the intestine: In-vivo and in-vitro evaluation of an indomethacin-lecithin conjugate, J. Control. Release, 2007, 119, 86-93.
11. A. Dahan.; R. Duvdevani.; I. Shapiro.; A. Elmann.; E. Finkelstein.; A. Hoffman. The oral absorption of phospholipid prodrugs: In vivo and in vitro mechanistic investigation of trafficking of a lecithinvalproic acid conjugate following oral administration. J. Control. Release, 2008, 126, 1-9.
12. M.M. Haapamaki.; J.M. Gronroos.; H. Nurmi.; K. Alanen.; T.J. Nevalainen. Gene expression of group II phospholipase A2 in intestine in Crohn’s disease, Am. J. Gastroenterol., 1999, 94, 713-720.
13. I. Lilja.; K. Smedh.; G. Olaison.; R. Sjödahl.; C. Tagesson.; C. Gustafson-Svärd. Phospholipase A2 gene expression and activity in histologically normal ileal mucosa and in Crohn’s ileitis, Gut, 1995, 37, 380-385.
14. T. Minami.; H. Tojo.; Y. Shinomura.; Y. Matsuzawa.; M. Okamoto. Increased group II phospholipase A2 in colonic mucosa of patients with Crohn’s disease and ulcerative colitis, Gut, 1994, 35, 1593-1598.
15. M.M. Haapamäki.; J.M. Grönroos.; H. Nurmi.; K. Alanen.; M. Kallajoki.; T.J. Nevalainen. Gene expression of group II phospholipase A2 in intestine in ulcerative colitis, Gut, 1997, 40, 95-101.
16. M. Haapamäki.; J. Grönroos.; H. Nurmi.; K. Irjala.; K. Alanen.; T. Nevalainen. Phospholipase A2 in serum and colonic mucosa in ulcerative colitis, Scand. J. Clin. Lab. Invest., 1999, 59, 279-287.
17. A. Arouri.; J. Trojnar.; S. Schmidt.; A.H. Hansen.; J. Mollenhauer.; O.G. Mouritsen. Development of a cell-based bioassay for phospholipase A2-triggered liposomal drug release, PLoS ONE, 2015, 10, e0125508.
18. A.H. Hansen.; O.G. Mouritsen.; A. Arouri. Enzymatic action of phospholipase A2 on liposomal drug delivery systems, Int. J. Pharm., 2015, 491, 49-57.
19. O. Korb.; P.W. Finn.; G. Jones. The cloud and other new computational methods to improve molecular modelling, Expert Opin. Drug Discov., 2014, 9, 1121-1131.
20. T.P. Straatsma.; H.J.C. Berendsen. Free energy of ionic hydration: Analysis of a thermodynamic integration technique to evaluate free energy differences by molecular dynamics simulations, J. Chem. Phy., 1988, 89, 5876-5886.
21. S. Kumar.; J.M. Rosenberg.; D. Bouzida.; R.H. Swendsen.; P.A. Kollman. The weighted histogram analysis method for free-energy calculations on biomolecules. I. The method. J. Comput. Chem., 1992, 13, 1011-1021.
22. J.D. Chodera.; D.L. Mobley.; M.R. Shirts.; R.W. Dixon.; K. Branson.; V.S. Pande. Alchemical free energy methods for drug discovery: progress and challenges, Curr. Opin. Structural Biol., 2011, 21, 150-160.
23. J. Michel.; J. Essex. Prediction of protein-ligand binding affinity by free energy simulations: assumptions, pitfalls and expectations. J. Comput. Aided Mol. Des., 2010, 24, 639-658.
24. T. Steinbrecher.; I. Joung.; D.A. Case. Soft-core potentials in thermodynamic integration: Comparing one-and two-step transformations. J. Comput. Chem., 2011, 32, 3253-3263.